It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Radiotherapy response of rectal cancer patients is dependent on a myriad of molecular mechanisms including response to stress, cell death, and cell metabolism. Modulation of lipid metabolism emerges as a unique strategy to improve radiotherapy outcomes due to its accessibility by bioactive molecules within foods. Even though a few radioresponse modulators have been identified using experimental techniques, trying to experimentally identify all potential modulators is intractable. Here we introduce a machine learning (ML) approach to interrogate the space of bioactive molecules within food for potential modulators of radiotherapy response and provide phytochemically-enriched recipes that encapsulate the benefits of discovered radiotherapy modulators. Potential radioresponse modulators were identified using a genomic-driven network ML approach, metric learning and domain knowledge. Then, recipes from the Recipe1M database were optimized to provide ingredient substitutions maximizing the number of predicted modulators whilst preserving the recipe’s culinary attributes. This work provides a pipeline for the design of genomic-driven nutritional interventions to improve outcomes of rectal cancer patients undergoing radiotherapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Imperial College London, Department of Computing, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
2 Imperial College London, Department of Computing, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Prescient Design, Genentech, Basel, Switzerland (GRID:grid.417570.0) (ISNI:0000 0004 0374 1269)
3 North Middlesex University Hospital, London, UK (GRID:grid.439355.d) (ISNI:0000 0000 8813 6797)
4 Imperial College London, Department of Surgery and Cancer, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
5 Royal Free Hospital, London, UK (GRID:grid.426108.9) (ISNI:0000 0004 0417 012X)
6 University of Oxford, Department of Computer Science, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
7 Prescient Design, Genentech, Basel, Switzerland (GRID:grid.417570.0) (ISNI:0000 0004 0374 1269); Yale University, Department of Environmental Health Sciences, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710)